Held by 4 specialist biotech funds
High Convergence# Signal Note: Driehaus Capital Initiates CBIO Position Driehaus Capital's $3.6M entry into Crescent Biopharma suggests conviction in the company's pipeline, likely centered on CB-5083 (an Hsp90 inhibitor in development for multiple myeloma and other hematologic malignancies).
AI analyst context — unlock full analysis
# Signal Note: BVF Partners Initiates CBIO Position BVF's $32.6M entry into Crescent Biopharma signals conviction in the company's clinical-stage pipeline, primarily driven by potential near-term catalysts around its lead asset CB1311 (FGFR inhibitor for solid tumors). Lampert's concentrated biotech value mandate typically targets mispriced asymmetric risk-reward, suggesting the market may be undervaluing upcoming Phase 2 data readouts or partnership potential. Key near-term catalysts will be clinical updates and clarity on the commercial viability of its oncology assets relative to current valuation.
+ 2more — see how much conviction went in
See the Full Story